This study is not yet accepting patients

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

a study on Prostate Cancer

Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
study ends around
Principal Investigator
by Michael Daneshvar (uci)

Description

Summary

This is a phase II single arm, open-label clinical trial determining diagnostic accuracy of Flotufolastat F18 PET in subjects with prostate adenocarcinoma. These are subjects who have not previously received treatment for prostate cancer.

Keywords

Prostate Adenocarcinoma, Prostate Cancer, Prostatic Neoplasms, Flotufolastat F18 PET, Post-Focal Therapy Flotufolastat F18PET

Eligibility

You can join if…

Open to males ages 18 years and up

  • Age 18 years or greater at time of consent
  • Prostate adenocarcinoma (no other histologic subtypes allowed)
  • Prostate Cancer planned to be treated by focal therapy (e.g. cryotherapy, HIFU, or NanoKnife)
  • Multiparametric-MRI imaging planned
  • Planned pre- and post- treatment MRI-fusion biopsy

You CAN'T join if...

  • Prior treatment for any prostate malignancy (e.g. radiation, focal therapy, or systemic therapy)
  • Genomic classifiers (e.g. Decipher) signifying intermediate or high-risk disease
  • PSA >10
  • High-risk prostate cancer (diagnosed by biopsy)
  • Bilateral prostatic lobe disease

Location

  • Chao Family Comprehensive Cancer Center, University of California, Irvine
    Orange California 92868 United States

Lead Scientist at University of California Health

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT07568756
Phase
Phase 2 Prostate Cancer Research Study
Study Type
Interventional
Participants
Expecting 60 study participants
Last Updated